LAG-3 / antibody combination / Oncologyoncology indicationsPhase IIIactive LCM ipilimumabYERVOY / CTLA-4 / monoclonal antibody / Oncologymultiple oncology indicationsPhase IIIactive LCM KarXTCOBENFY / muscarinic receptors / small molecule / Neuroscienceneuropsychiatric indicationsPhase IIIactive LCM milvexianFactor XIa / small molecule anticoagulant / Cardiovascularthrombotic disordersPhase IIIactive BMS-986278BMS-986278 / LPA1 / small molecule antagonist / Fibrosisidiopathic pulmonary fibrosisPhase IIIactive BMS-986495BMS-986495 / MTBR tau / antibody / NeuroscienceAlzheimer's diseasePhase IIactive imzokitugCCR8 / monoclonal antibody / Oncologysolid tumorsPhase I/IIactive obexelimabCD19
The figures above are research-context reference ranges, not a dosing recommendation
NCT03548987
The kind where you wake up feeling like a different person
The membranes were blocked with 5% nonfat dry milk in PBS supplemented with 0.1% (v/v) Tween 20 and incubated overnight at 4C with anti-CPT2, PPAR (Santa Cruz Biotechnology,United States), CPT1A, LCAD, Very long-chain acyl-CoA dehydrogenase (VLCAD), (Proteintech, United States), GAPDH (from Cell Signaling Technology, United States)
Pro-apoptotic effectors BAX and BAK oligomerize upon activation, inducing mitochondrial outer membrane permeabilization (MOMP), a crucial event during apoptosis [73, 74]
